Economic evaluation of intravenous immune globulin therapy for Kawasaki syndrome

Terry P. Klassen, Peter Rowe, Amiram Gafni

Research output: Contribution to journalArticle

Abstract

Objective: To determine the costs and clinical outcomes of three alternative treatments of the acute phase of Kawasaki syndrome: aspirin alone; low doses of intravenously administered immune globulin (IVIG-LD), 400 mg/kg per dose for 4 days; and high doses of intravenously administered immune globulin (IVIG-HD), 2.0 gm/kg for one dose. Design: A model was developed that assumed the inclusion of 100 patients with acute Kawasaki syndrome in each treatment option. Costs were valued by using the Chedoke-McMaster Corporate Cost Model in 1992 Canadian dollars. Clinical outcome, based on the published literature, was measured by the prevalence of coronary artery dilation at 7 weeks from the diagnosis of Kawasaki syndrome. Results: For every 100 patients with Kawasaki syndrome, the cost was reduced by $323,400 when aspirin therapy alone was changed to VIG-HD therapy and 14 cases of coronary artery dilation were therepy prevented. When IVIG-HD therapy was compared with IVIG-LD therapy, the cost was reduced by $118,200 because two cases of coronary artery aneurysm were prevented. This latter result was sensitive to the duration of hospitalization, with IVIG-HD costing $8500 more for every 100 patients than IVIG-LD when it was assumed that both groups were hospitalized for 5 days, an unlikely occurrence. Conclusions: Treatment with IVIG-HD for Kawasaki syndrome is preferred because it results in both lower costs and lower rates of coronary artery dilation.

Original languageEnglish (US)
Pages (from-to)538-542
Number of pages5
JournalJournal of Pediatrics
Volume122
Issue number4
DOIs
StatePublished - 1993

Fingerprint

Mucocutaneous Lymph Node Syndrome
Intravenous Immunoglobulins
Cost-Benefit Analysis
Costs and Cost Analysis
Coronary Vessels
Dilatation
Therapeutics
Aspirin
Immunoglobulins
Coronary Aneurysm
Hospitalization

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health

Cite this

Economic evaluation of intravenous immune globulin therapy for Kawasaki syndrome. / Klassen, Terry P.; Rowe, Peter; Gafni, Amiram.

In: Journal of Pediatrics, Vol. 122, No. 4, 1993, p. 538-542.

Research output: Contribution to journalArticle

Klassen, Terry P. ; Rowe, Peter ; Gafni, Amiram. / Economic evaluation of intravenous immune globulin therapy for Kawasaki syndrome. In: Journal of Pediatrics. 1993 ; Vol. 122, No. 4. pp. 538-542.
@article{f4387de46d494b5ba055fa30708d69bb,
title = "Economic evaluation of intravenous immune globulin therapy for Kawasaki syndrome",
abstract = "Objective: To determine the costs and clinical outcomes of three alternative treatments of the acute phase of Kawasaki syndrome: aspirin alone; low doses of intravenously administered immune globulin (IVIG-LD), 400 mg/kg per dose for 4 days; and high doses of intravenously administered immune globulin (IVIG-HD), 2.0 gm/kg for one dose. Design: A model was developed that assumed the inclusion of 100 patients with acute Kawasaki syndrome in each treatment option. Costs were valued by using the Chedoke-McMaster Corporate Cost Model in 1992 Canadian dollars. Clinical outcome, based on the published literature, was measured by the prevalence of coronary artery dilation at 7 weeks from the diagnosis of Kawasaki syndrome. Results: For every 100 patients with Kawasaki syndrome, the cost was reduced by $323,400 when aspirin therapy alone was changed to VIG-HD therapy and 14 cases of coronary artery dilation were therepy prevented. When IVIG-HD therapy was compared with IVIG-LD therapy, the cost was reduced by $118,200 because two cases of coronary artery aneurysm were prevented. This latter result was sensitive to the duration of hospitalization, with IVIG-HD costing $8500 more for every 100 patients than IVIG-LD when it was assumed that both groups were hospitalized for 5 days, an unlikely occurrence. Conclusions: Treatment with IVIG-HD for Kawasaki syndrome is preferred because it results in both lower costs and lower rates of coronary artery dilation.",
author = "Klassen, {Terry P.} and Peter Rowe and Amiram Gafni",
year = "1993",
doi = "10.1016/S0022-3476(05)83532-2",
language = "English (US)",
volume = "122",
pages = "538--542",
journal = "Journal of Pediatrics",
issn = "0022-3476",
publisher = "Mosby Inc.",
number = "4",

}

TY - JOUR

T1 - Economic evaluation of intravenous immune globulin therapy for Kawasaki syndrome

AU - Klassen, Terry P.

AU - Rowe, Peter

AU - Gafni, Amiram

PY - 1993

Y1 - 1993

N2 - Objective: To determine the costs and clinical outcomes of three alternative treatments of the acute phase of Kawasaki syndrome: aspirin alone; low doses of intravenously administered immune globulin (IVIG-LD), 400 mg/kg per dose for 4 days; and high doses of intravenously administered immune globulin (IVIG-HD), 2.0 gm/kg for one dose. Design: A model was developed that assumed the inclusion of 100 patients with acute Kawasaki syndrome in each treatment option. Costs were valued by using the Chedoke-McMaster Corporate Cost Model in 1992 Canadian dollars. Clinical outcome, based on the published literature, was measured by the prevalence of coronary artery dilation at 7 weeks from the diagnosis of Kawasaki syndrome. Results: For every 100 patients with Kawasaki syndrome, the cost was reduced by $323,400 when aspirin therapy alone was changed to VIG-HD therapy and 14 cases of coronary artery dilation were therepy prevented. When IVIG-HD therapy was compared with IVIG-LD therapy, the cost was reduced by $118,200 because two cases of coronary artery aneurysm were prevented. This latter result was sensitive to the duration of hospitalization, with IVIG-HD costing $8500 more for every 100 patients than IVIG-LD when it was assumed that both groups were hospitalized for 5 days, an unlikely occurrence. Conclusions: Treatment with IVIG-HD for Kawasaki syndrome is preferred because it results in both lower costs and lower rates of coronary artery dilation.

AB - Objective: To determine the costs and clinical outcomes of three alternative treatments of the acute phase of Kawasaki syndrome: aspirin alone; low doses of intravenously administered immune globulin (IVIG-LD), 400 mg/kg per dose for 4 days; and high doses of intravenously administered immune globulin (IVIG-HD), 2.0 gm/kg for one dose. Design: A model was developed that assumed the inclusion of 100 patients with acute Kawasaki syndrome in each treatment option. Costs were valued by using the Chedoke-McMaster Corporate Cost Model in 1992 Canadian dollars. Clinical outcome, based on the published literature, was measured by the prevalence of coronary artery dilation at 7 weeks from the diagnosis of Kawasaki syndrome. Results: For every 100 patients with Kawasaki syndrome, the cost was reduced by $323,400 when aspirin therapy alone was changed to VIG-HD therapy and 14 cases of coronary artery dilation were therepy prevented. When IVIG-HD therapy was compared with IVIG-LD therapy, the cost was reduced by $118,200 because two cases of coronary artery aneurysm were prevented. This latter result was sensitive to the duration of hospitalization, with IVIG-HD costing $8500 more for every 100 patients than IVIG-LD when it was assumed that both groups were hospitalized for 5 days, an unlikely occurrence. Conclusions: Treatment with IVIG-HD for Kawasaki syndrome is preferred because it results in both lower costs and lower rates of coronary artery dilation.

UR - http://www.scopus.com/inward/record.url?scp=0027398892&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027398892&partnerID=8YFLogxK

U2 - 10.1016/S0022-3476(05)83532-2

DO - 10.1016/S0022-3476(05)83532-2

M3 - Article

C2 - 8463897

AN - SCOPUS:0027398892

VL - 122

SP - 538

EP - 542

JO - Journal of Pediatrics

JF - Journal of Pediatrics

SN - 0022-3476

IS - 4

ER -